| Literature DB >> 33115722 |
Ajit P Limaye1, Tara M Babu2,3, Michael Boeckh4,5.
Abstract
Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new approaches and remaining challenges to the optimal control of CMV infection and disease in transplant settings.Entities:
Keywords: antiviral agents; clinical trials; cytomegalovirus; diagnostics; immune monitoring; immunocompromised hosts; transplant infectious diseases; transplantation; vaccines
Year: 2020 PMID: 33115722 PMCID: PMC7920732 DOI: 10.1128/CMR.00043-19
Source DB: PubMed Journal: Clin Microbiol Rev ISSN: 0893-8512 Impact factor: 26.132